Camilla Sylvest
Camilla Sylvest is the executive vice-president of commercial strategy and corporate affairs at Novo Nordisk. In a recent interview, she discussed the company's commitment to investigating the health benefits of its semaglutide drug, particularly in relation to addiction and its potential role in reducing cravings, highlighting the ongoing research into the broader applications of GLP-1 medications.
Born on Jan 01, 1971 (54 years old)
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Ireland:
Camilla Sylvest, the Novo Nordisk executive in charge of new drug roll-out, discussed the expected access to Wegovy.
8
Ireland:
Camilla Sylvest is the executive vice-president of commercial strategy and corporate affairs at Novo Nordisk, overseeing the launch of the obesity drug Wegovy in Ireland.
8
Ireland:
Camilla Sylvest, executive vice-president of commercial strategy and corporate affairs at Novo Nordisk, emphasized the company's commitment to pursuing health contributions of its semaglutide drug.
8